Lotta J. Seppala

Lotta J. Seppala

Auto-generated profile, based on publicly available information

Lotta J. Seppala

Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
LSLotta J. Seppala
Lotta J. Seppala
AWAnne M.A.T. Wermelink
Anne M.A.T. Wermelink
MVMax de Vries
Max de Vries
KPKimberley J. Ploegmakers
Kimberley J. Ploegmakers
EGEsther M.M. van de Glind
Esther M.M. van de Glind
HTHeinrich Thaler
Heinrich Thaler

1 April 2018 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
LSLotta J. Seppala
Lotta J. Seppala
EGEsther M.M. van de Glind
Esther M.M. van de Glind
JDJoost G. Daams
Joost G. Daams
KPKimberley J. Ploegmakers
Kimberley J. Ploegmakers
MVMax de Vries
Max de Vries
HTHeinrich Thaler
Heinrich Thaler

1 April 2018 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
MVMax de Vries
Max de Vries
LSLotta J. Seppala
Lotta J. Seppala
JDJoost G. Daams
Joost G. Daams
EGEsther M.M. van de Glind
Esther M.M. van de Glind
TMTahir Masud
Tahir Masud
HTHeinrich Thaler
Heinrich Thaler

22 December 2020 in Age and Ageing
Verified
Journal Article
Open access
PDF file
LSLotta J Seppala
Lotta J Seppala
MPMirko Petrovic
Mirko Petrovic
JRJesper Ryg
Jesper Ryg
Gülistan BahatGülistan Bahat
Gülistan Bahat
ETEva Topinkova
Eva Topinkova
NVNathalie van der Velde
Nathalie van der Velde
Background: Healthcare professionals are often reluctant to deprescribe fall-risk-increasing drugs (FRIDs). Lack of knowledge and skills form a significant barrier and furthermore, there is no consensus on which medications are considered as FRIDs despite several systematic reviews. To support clinicians in the management of FRIDs and to facilitate the deprescribing process, STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk) and a deprescribing tool were developed by a European expert group. Methods: STOPPFall was created by two facilitators based on evidence from recent meta-analyses and national fall prevention guidelines in Europe. Twenty-four panellists chose their level of agreement on a Likert scale with the items in the STOPPFall in three Delphi panel rounds. A threshold of 70% was selected for consensus a priori. The panellists were asked whether some agents are more fall-risk-increasing than others within the same pharmacological class. In an additional questionnaire, panellists were asked in which cases deprescribing of FRIDs should be considered and how it should be performed. Results: The panellists agreed on 14 medication classes to be included in the STOPPFall. They were mostly psychotropic medications. The panellists indicated 18 differences between pharmacological subclasses with regard to fall-risk-increasing properties. Practical deprescribing guidance was developed for STOPPFall medication classes. Conclusion: STOPPFall was created using an expert Delphi consensus process and combined with a practical deprescribing tool designed to optimise medication review. The effectiveness of these tools in falls prevention should be further evaluated in intervention studies.

23 September 2022 in Age and Ageing
Verified
Journal Article
Open access
PDF file
LSLotta J Seppala
Lotta J Seppala
NKNellie Kamkar
Nellie Kamkar
EPEveline van Poelgeest
Eveline van Poelgeest
KTKatja Thomsen
Katja Thomsen
JDJoost G Daams
Joost G Daams
NVNathalie van der Velde
Nathalie van der Velde
Our aim was to assess the effectiveness of medication review and deprescribing interventions as a single intervention in falls prevention. systematic review and meta-analysis. Medline, Embase, Cochrane CENTRAL, PsycINFO until 28 March 2022. randomised controlled trials of older participants comparing any medication review or deprescribing intervention with usual care and reporting falls as an outcome. title/abstract and full-text screening by two reviewers. Cochrane Collaboration revised tool. results reported separately for different settings and sufficiently comparable studies meta-analysed. forty-nine heterogeneous studies were included. meta-analyses of medication reviews resulted in a risk ratio (RR) of 1.05 (95% confidence interval, 0.85–1.29, I2 = 0%, 3 studies(s)) for number of fallers, in an RR = 0.95 (0.70–1.27, I2 = 37%, 3 s) for number of injurious fallers and in a rate ratio (RaR) of 0.89 (0.69–1.14, I2 = 0%, 2 s) for injurious falls. meta-analyses assessing medication reviews resulted in an RR = 0.97 (0.74–1.28, I2 = 15%, 2 s) and in an RR = 0.50 (0.07–3.50, I2 = 72% %, 2 s) for number of fallers after and during admission, respectively. meta-analyses investigating medication reviews or deprescribing plans resulted in an RR = 0.86 (0.72–1.02, I2 = 0%, 5 s) for number of fallers and in an RaR = 0.93 (0.64–1.35, I2 = 92%, 7 s) for number of falls. the heterogeneity of the interventions precluded us to estimate the exact effect of medication review and deprescribing as a single intervention. For future studies, more comparability is warranted. These interventions should not be implemented as a stand-alone strategy in falls prevention but included in multimodal strategies due to the multifactorial nature of falls. PROSPERO registration number: CRD42020218231

9 October 2023 in European Geriatric Medicine
Verified
Journal Article
Open access
PDF file
EPEveline van Poelgeest
Eveline van Poelgeest
LSLotta Seppala
Lotta Seppala
Gülistan BahatGülistan Bahat
Gülistan Bahat
BIBirkan Ilhan
Birkan Ilhan
AMAlpana Mair
Alpana Mair
TPthe EuGMS SIG Pharmacology
the EuGMS SIG Pharmacology
Inappropriate polypharmacy is highly prevalent among older adults and presents a significant healthcare concern. Conducting medication reviews and implementing deprescribing strategies in multimorbid older adults with polypharmacy are an inherently complex and challenging task. Recognizing this, the Special Interest Group on Pharmacology of the European Geriatric Medicine Society has compiled evidence on medication review and deprescribing in older adults and has formulated recommendations to enhance appropriate prescribing practices. The current evidence supports the need for a comprehensive and widespread transformation in education, guidelines, research, advocacy, and policy to improve the management of polypharmacy in older individuals. Furthermore, incorporating deprescribing as a routine aspect of care for the ageing population is crucial. We emphasize the importance of involving geriatricians and experts in geriatric pharmacology in driving, and actively participating in this transformative process. By doing so, we can work towards achieving optimal medication use and enhancing the well-being of older adults in the generations to come.